Anti-JL1 antibody-conjugated poly (L-lysine) for targeted gene delivery to leukemia T cells

被引:60
作者
Suh, WH
Chung, JK
Park, SH
Kim, SW
机构
[1] Univ Utah, Ctr Controlled Chem Delivery, Dept Pharmaceut & Pharmaceut Chem, Salt Lake City, UT 84112 USA
[2] Seoul Natl Univ, Dept Nucl Med, Seoul, South Korea
[3] Seoul Natl Univ Hosp, Dept Pathol, Seoul 110744, South Korea
关键词
gene delivery; plasmid; leukemia; Molt; 4; cell; anti-JL1; antibody;
D O I
10.1016/S0168-3659(01)00273-5
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
We have designed the gene delivery carrier targeted to Molt 4 cells, human leukemia T cells, using monoclonal antibody against leukemia-specific JL1 antigen, anti-JL1 antibody, as a targeting moiety. Anti-JL1 antibody has been proven to bind to JL1 antigen and subsequently be internalized into Molt 4 cells, demonstrating that anti-JL1 antibody has the potential as a targeting ligand for leukemia-specific gene transfer. Anti-JL1 antibody was modified with the heterobifunctional crosslinker, PDPH, at carbohydrate sites and conjugated to thiolated poly-L-lysine (PLL) via disulfide bridges. The composition and antigen binding affinity of antibody-PLL conjugates were analyzed by the amino acid analysis and the flow cytometry, respectively. Antibody-PLL conjugates neutralized pSV-beta -galactosidase plasmid DNA at 5:1 weight ratio and condensed into about 200-300-nm complexes. DNA/antibody-PLL complexes were effectively internalized into Molt 4 cells after 4 h incubation at 37 degreesC and showed significantly higher in vitro transfection efficiency than DNA/PLL complexes and DNA/Lipofectin(TM) formulation due to the targeting effect of receptor-mediated endocytosis induced by anti-JL1 antibody. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:171 / 178
页数:8
相关论文
共 16 条
[1]  
BENNS JM, IN PRESS J DRUG TARG
[2]   PROTEIN THIOLATION AND REVERSIBLE PROTEIN-PROTEIN CONJUGATION - N-SUCCINIMIDYL 3-(2-PYRIDYLDITHIO)PROPIONATE, A NEW HETEROBIFUNCTIONAL REAGENT [J].
CARLSSON, J ;
DREVIN, H ;
AXEN, R .
BIOCHEMICAL JOURNAL, 1978, 173 (03) :723-737
[3]   Characterization of a targeted gene carrier, lactose-polyethylene glycol-grafted poly-L-lysine, and its complex with plasmid DNA [J].
Choi, YH ;
Liu, F ;
Choi, JS ;
Kim, SW ;
Park, JS .
HUMAN GENE THERAPY, 1999, 10 (16) :2657-2665
[4]   Gene transfer with synthetic virus-like particles via the integrin-mediated endocytosis pathway [J].
Erbacher, P ;
Remy, JS ;
Behr, JP .
GENE THERAPY, 1999, 6 (01) :138-145
[5]  
Garnett MC, 1999, CRIT REV THER DRUG, V16, P147
[6]  
HERMANSON GT, 1996, BIOCONJUGATE TECHNIQ, P64
[7]  
Huang L., 1999, NONVIRAL VECTORS GEN
[8]   Terplex DNA delivery system as a gene carrier [J].
Kim, JS ;
Maruyama, A ;
Akaike, T ;
Kim, SW .
PHARMACEUTICAL RESEARCH, 1998, 15 (01) :116-121
[9]   A new non-viral DNA delivery vector: the terplex system [J].
Kim, JS ;
Kim, BI ;
Maruyama, A ;
Akaike, T ;
Kim, SW .
JOURNAL OF CONTROLLED RELEASE, 1998, 53 (1-3) :175-182
[10]   Nonviral gene therapy: promises and challenges [J].
Li, S ;
Huang, L .
GENE THERAPY, 2000, 7 (01) :31-34